Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has reported earnings for its fourth fiscal quarter (ending December 31) of $1.50 versus a loss $-3.82 for the same period a year ago. This result fell short of the consensus estimate of $5.18 by $-3.68. For the latest four quarters through December 31, E.P.S. were $6.55 versus $-3.58 for the same period a year ago.
Recent Price Action
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stock declined modestly by -1.9% on 2/28/24. The stock closed at $129.70. Moreover, above average trading volume at 129% of normal accompanied the decline. The stock has performed in line with the market over the last nine months and has risen 2.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, JAZZ is expected to continue to be a major Value Builder.
Jazz Pharmaceuticals plc has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Jazz Pharmaceuticals plc has a good Appreciation Score of 79 but a neutral Power Rating of 41, triggering the High Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment